Clinical trial NCT04589468: Researching the Effect of Exercise on Cancer
Official title: Phase 1a/b Trial of Exercise as Interception Therapy for Primary High-Risk Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Breast Cancer
Prostate Cancer
Colorectal Cancer
Stage I Breast Cancer
Stage II Breast Cancer
Stage III Breast Cancer
Stage I Prostate Cancer
Stage II Prostate Cancer
Stage III Prostate Cancer
Stage I Colorectal Cancer
Stage II Colorectal Cancer
Stage III Colorectal Cancer
Keywords: Breast Cancer
Prostate Cancer
Colorectal Cancer
exercise
ctDNA
20-378
Memorial Sloan Kettering Cancer Center
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2020-10-19
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: PREVENTION

Brief summary: Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that stimulates and strengthens the heart and lungs and improves the body's use of oxygen) can reduce the level of ctDNA found in the blood. During the study, the highest level of exercise that is practical, is safe, and has positive effects on the body that may prevent the return of cancer (including a decrease in ctDNA levels) will be found. Each level of exercise tested will be a certain number of minutes each week. Once the best level of exercise is found, it will be tested further in a new group of participants. All participants in this study will have been previously treated for breast, prostate, or colorectal cancer.


Eligibility criteria: Inclusion Criteria:

* Postsurgical diagnosis of patients with primary solid tumors at high-risk of relapse as defined by one of the following:

  ° High-risk primary solid tumor (e.g., colorectal, ovarian, non-small cell lung cancer) (colorectal cancer only for Phase 1a)
* Stage 3 or
* ctDNA positive

  ° High-risk breast cancer
* Residual invasive disease in the breast or the lymph nodes following completion of neoadjuvant chemotherapy (NACT),
* Estrogen receptor (ER), and/or progesterone receptor (PR) positive and HER2 negative,
* CPS-EG score ≥ 3,
* CPS-EG score ≥2 w ith ypN+, or
* Recurrence score ≥ 25
* No evidence of disease
* Age ≥ 18
* Interval of ≥ 1 month but ≤ 2 years following completion of all definitive adjuvant therapy
* Non-exercising (i.e., \< 30 minutes of moderate and \< 20 mins of vigorous exercise/wk), as assessed by remote activity and heart rate tracking for a 7-day period prior to study entry)

  ° If ≥ 30 minutes but less than 45 minutes of moderate exercise/week, or if ≥ 20 minutes but less than 30 minutes of vigorous exercise/week, patients may be eligible, at the discretion of the PI.
* Cleared for exercise participation as per screening clearance via PAR-Q+
* Willingness to comply with all study-related procedures

Exclusion Criteria:

* Enrollment onto any other interventional investigational study except interventions determined by the PI not to confound study outcomes
* Any other current diagnosis of invasive cancer of any kind
* Distant metastatic malignancy of any kind
* Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation

Primary outcomes:
measure: Identify the recommended phase 2 dose (RP2D) of exercise for testing in the phase 1b.
timeFrame: 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: San Carlos
country: United States
facility: Natera, Inc. (Data or Specimen Analysis Only)
state: California
city: Basking Ridge
country: United States
facility: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
state: New Jersey
city: Middletown
country: United States
facility: Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
state: New Jersey
city: Montvale
country: United States
facility: Memorial Sloan Kettering Bergen (Limited Protocol Activities)
state: New Jersey
city: Commack
country: United States
facility: Memorial Sloan Kettering Commack (Limited Protocol Activities)
state: New York
city: Harrison
country: United States
facility: Memorial Sloan Kettering Westchester (Limited Protocol Activities)
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Uniondale
country: United States
facility: Memorial Sloan Kettering Nassau (Limited Protocol Activities)
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Lee Jones, PhD
role: PRINCIPAL_INVESTIGATOR
References: